Zastaprazan's effect on clopidogrel platelet response after PCI

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 4 interventional study compares zastaprazan and rabeprazole when given with clopidogrel in patients with chronic coronary syndrome who have undergone PCI and will remain on dual antiplatelet therapy. The primary outcome is platelet reactivity measured while patients receive the assigned acid-suppressing drug alongside clopidogrel. The protocol focuses on possible drug–drug interactions mediated by CYP2C19 and aims to define an optimal combination that balances antiplatelet efficacy and gastrointestinal protection. Rabeprazole is included as a comparator because it is known to have relatively low CYP2C19 inhibition among PPIs.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 19 years or older at the time of providing informed consent.
2. Patients with Chronic Coronary Syndrome (CCS) who have undergone Percutaneous Coronary Intervention (PCI) and agreed to participate in the study.
3. Patients who are required to maintain dual antiplatelet therapy (DAPT) including clopidogrel for at least 6 months after PCI.
4. Patients who have voluntarily provided written informed consent to participate in this clinical study.

Exclusion Criteria:

1. History of hypersensitivity to P-CABs, PPIs, benzimidazoles, aspirin, clopidogrel, or any of the excipients in the study drugs.
2. History of or planned surgery that may affect gastric acid secretion, such as upper gastrointestinal resection, acid suppression surgery, or gastric mucosal resection. (However, patients who have undergone simple perforation repair of the stomach or duodenum, appendectomy, cholecystectomy, hysterectomy, or endoscopic/laparoscopic resection of benign tumors are eligible).
3. Diagnosis of Zollinger-Ellison syndrome or inflammatory diseases (e.g., pancreatitis, or inflammatory bowel diseases such as Crohn's disease or ulcerative colitis).
4. Currently receiving HIV protease inhibitors (atazanavir, nelfinavir) or rilpivirine-containing products.
5. Abnormal blood chemistry values within 4 weeks prior to screening: AST, ALT, ALP, or total bilirubin \> 3 times the upper limit of normal (ULN). Estimated Glomerular Filtration Rate (eGFR) \< 30 mL/min/1.73m², calculated using the IDMS-traceable MDRD equation.
6. Recent Medication Use: Use of medications expected to affect the study results, such as P2Y12 inhibitors (other than the prescribed clopidogrel), within 2 weeks prior to baseline.
7. Pregnant or lactating women, or women with a positive pregnancy test.
8. Patients with hereditary problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

Where it's running

• Yongin Severance Hospital, Yonsei University
  Yongin-si, Gyeonggi-do, South Korea Recruiting

Study contacts

• Study coordinator: Yongcheol Kim, MD, PhD
• Email: yongcheol@yuhs.ac
• Phone: +82-031-5189-8967

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Common femoral vein-to-artery diameter ratio to detect elevated LVEDP

  Researchers test whether the ratio of the common femoral vein to artery diameters, measured by ultrasound, can flag elevated LV end-diastolic pressure in patients having coronary angiography.

  Recruiting Burapha University · Chon Buri · NCT07866859

• Aspirin 50 mg vs 100 mg with a P2Y12 inhibitor after PCI

  This trial tests whether a 50 mg daily aspirin dose, when used with a P2Y12 inhibitor after PCI, works as well as 100 mg with similar safety for people staying on DAPT for 12 months.

  Recruiting Jilin University · Changchun, Jilin · NCT07846462

• See if stopping long-term aspirin is as good as continuing it in older adults with stable ischemic heart disease

  In adults 65 and older with stable ischemic heart disease, this trial tests whether stopping daily low-dose aspirin is not worse than continuing it.

  Recruiting at 2 sites Phase 4 Odense University Hospital · Copenhagen and 1 other locations · NCT07795398

• IVUS-Guided Left Main Stenting: IVUS-Guided vs Trained-Eye Approach

  This trial tests whether using IVUS to guide left main bifurcation stenting is as good as using an angiography-driven, experience-based approach by an IVUS-savvy operator.

  Recruiting Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health · Saint Petersburg · NCT07711106

• Can CZT-SPECT/CT quantify myocardial tracer uptake to match PET measurements in coronary artery disease?

  This study tests whether CZT-SPECT/CT can quantify heart blood flow at rest and stress and see if the results align with PET measurements for people with coronary artery disease.

  Recruiting Centre Hospitalier Régional d'Orléans · Orléans, Loiret · NCT07708805

• Ultrasound vs CT calcium scoring to reclassify symptomatic chest pain

  This study tests whether carotid ultrasound can reclassify risk in adults with chest pain and suspected chronic coronary syndrome, compared with the CT calcium score.

  Recruiting London North West Healthcare NHS Trust · Harrow · NCT07696533

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.